JP6265979B2 - チエノトリアゾロジアゼピン化合物を使用するリンパ腫の治療方法 - Google Patents
チエノトリアゾロジアゼピン化合物を使用するリンパ腫の治療方法 Download PDFInfo
- Publication number
- JP6265979B2 JP6265979B2 JP2015517810A JP2015517810A JP6265979B2 JP 6265979 B2 JP6265979 B2 JP 6265979B2 JP 2015517810 A JP2015517810 A JP 2015517810A JP 2015517810 A JP2015517810 A JP 2015517810A JP 6265979 B2 JP6265979 B2 JP 6265979B2
- Authority
- JP
- Japan
- Prior art keywords
- cell
- formula
- lymphoma
- compound
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Description
22個のびまん性大細胞型B細胞リンパ腫(DLBCL)、8個の未分化大T細胞リンパ腫(ALCL)、4個のマントル細胞リンパ腫(MCL)、および3個の脾臓周辺帯リンパ腫(SMZL)樹立ヒト細胞系において、式2の抗増殖活性を評価した。10% ウシ胎児血清、1% L−グルタミンおよびペニシリン−ストレプトマイシン−ネオマイシン(〜5,000単位のペニシリン、5mg/mLのストレプトマイシン、10mg/mLのネオマイシン)で補足されたRPMI−1640(GIBCO Invitrogen,Basel,Switzerland)またはDMEM(GIBCO Invitrogen,Basel,Switzerland)培地内で細胞系を培養した。
米国特許出願公開第20100286127号(その全体を参照により本明細書に組み入れることとする)に開示されているとおり、式2の化合物はBETブロモドメインタンパク質2、3および4(BRD2、BRD3、BRD4)の競合的インヒビターであることが既に示されている。BRD4の阻害はc−MYC癌遺伝子のダウンレギュレーションを引き起こすことが示されている[Delmore JE,Issa GC,LemieuxMEら:BET bromodomain inhibition as a therapeutic strategy to target c−Myc.Cell 2011;146:1−14]。したがって、BRD2、BRD3およびBRD4のmRNAおよびタンパク質の基底レベル、ならびにc−MYCのmRNAおよびタンパク質レベルに対する式2の化合物の効果を、選択されたDLBCLおよびALCL細胞系において評価した。
式2の化合物は、米国特許出願公開第20100286127号に開示されているとおり、BETブロモドメインタンパク質2、3および4(BRD2、BRD3、BRD4)の競合的インヒビターであることが既に示されており、BRD4は、ある状況において腫瘍抑制因子として作用しうる転写因子NFκBの調節に関与すると報告されている[Huang B,Yang XD,Zhou MM,Ozato K,Chen LF:Brd4 coactivates transcriptional activation of NF−κB via specific binding to acetylated RelA.Mol Cell Biol 2009;29:1375−1387]。したがって、NFκB標的(IRF4、A20、BIRC3)のmRNA発現に対する式2の化合物の効果を5個のDLBCL(DoHH2、Karpas 422、SU−DHL−2、SU−DHL−6、U2932)細胞系において評価した。結果は、式2の化合物がNFκB標的のダウンレギュレーションを誘導することを示した。代表的な結果を図9に示す。
Claims (1)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261663885P | 2012-06-25 | 2012-06-25 | |
US61/663,885 | 2012-06-25 | ||
US201261670918P | 2012-07-12 | 2012-07-12 | |
US61/670,918 | 2012-07-12 | ||
PCT/EP2013/063313 WO2014001356A1 (en) | 2012-06-25 | 2013-06-25 | Method of treating lymphoma using thienotriazolodiazepine compounds |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2015531747A JP2015531747A (ja) | 2015-11-05 |
JP2015531747A5 JP2015531747A5 (ja) | 2016-07-28 |
JP6265979B2 true JP6265979B2 (ja) | 2018-01-24 |
Family
ID=48672651
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015517810A Expired - Fee Related JP6265979B2 (ja) | 2012-06-25 | 2013-06-25 | チエノトリアゾロジアゼピン化合物を使用するリンパ腫の治療方法 |
Country Status (12)
Country | Link |
---|---|
US (1) | US20140018353A1 (ja) |
EP (1) | EP2863923B1 (ja) |
JP (1) | JP6265979B2 (ja) |
KR (1) | KR20150045423A (ja) |
CN (1) | CN105050605A (ja) |
AU (1) | AU2013283378B2 (ja) |
BR (1) | BR112014032105A2 (ja) |
CA (1) | CA2877434A1 (ja) |
IN (1) | IN2014DN11269A (ja) |
MX (1) | MX2014015986A (ja) |
RU (1) | RU2659171C2 (ja) |
WO (1) | WO2014001356A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016525563A (ja) * | 2013-08-01 | 2016-08-25 | オンコエシックス ゲーエムベーハー | チエノトリアゾロジアゼピン化合物を含む医薬製剤 |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3608317A1 (en) | 2012-01-12 | 2020-02-12 | Yale University | Compounds & methods for the enhanced degradation of targeted proteins & other polypeptides by an e3 ubiquitin ligase |
US9227985B2 (en) | 2013-03-15 | 2016-01-05 | Incyte Corporation | Tricyclic heterocycles as bet protein inhibitors |
US9290514B2 (en) | 2013-07-08 | 2016-03-22 | Incyte Holdings Corporation | Tricyclic heterocycles as BET protein inhibitors |
WO2015018520A1 (en) * | 2013-08-06 | 2015-02-12 | Oncoethix Sa | A bet-brd inhibitor represents a novel agent for alk positive anaplastic large cell lymphoma |
CN105899212A (zh) * | 2013-08-06 | 2016-08-24 | 翁科埃斯克斯有限公司 | 利用β溴结构域抑制剂治疗弥漫性大B细胞淋巴瘤(DLBCL)的方法 |
WO2015018522A1 (en) * | 2013-08-06 | 2015-02-12 | Oncoethix Sa | Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large b-cell lymphoma (dlbcl) |
WO2015081203A1 (en) | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
US9315501B2 (en) | 2013-11-26 | 2016-04-19 | Incyte Corporation | Bicyclic heterocycles as BET protein inhibitors |
US9757385B2 (en) | 2013-11-27 | 2017-09-12 | Merck Sharp & Dohme Corp. | Method of treating leukemia using pharmaceutical formulation containing thienotriazolodiazepine compounds |
WO2015095492A1 (en) | 2013-12-19 | 2015-06-25 | Incyte Corporation | Tricyclic heterocycles as bet protein inhibitors |
HUE061770T2 (hu) | 2014-04-23 | 2023-08-28 | Incyte Holdings Corp | 1H-pirrolo[2,3-C]piridin-7(6H)-onok és pirazolo[3,4-C]piridin-7(6H)-onok mint BET fehérjék gátlószerei |
WO2015168621A1 (en) | 2014-05-02 | 2015-11-05 | Oncoethix Sa | Method of treating acute myeloid leukemia and/or acute lymphoblastic leukemia using thienotriazolodiazepine compounds |
EP3137086A4 (en) * | 2014-05-02 | 2017-12-27 | Oncoethix GmbH | Method of treating resistant non-hodgkin lymphoma, medulloblastoma, and/or alk+non-small cell lung cancer using thienotriazolodiazepine compounds |
WO2015169951A1 (en) | 2014-05-08 | 2015-11-12 | Oncoethix Gmbh | Method of treating triple-negative breast cancer using thienotriazolodiazepine compounds |
CN106852119A (zh) | 2014-06-13 | 2017-06-13 | 翁科埃斯克斯有限公司 | 利用噻吩并三唑并二氮杂*化合物治疗非小细胞肺癌和/或小细胞肺癌的方法 |
JP2017528446A (ja) | 2014-08-19 | 2017-09-28 | オンコエシックス ゲーエムベーハー | チエノトリアゾロジアゼピン化合物を用いるリンパ腫の治療方法 |
US9527864B2 (en) | 2014-09-15 | 2016-12-27 | Incyte Corporation | Tricyclic heterocycles as BET protein inhibitors |
KR101675984B1 (ko) * | 2015-02-23 | 2016-11-14 | 한양대학교 에리카산학협력단 | 티에노디아제핀 유도체 또는 이의 약학적으로 허용가능한 염, 및 이를 유효성분으로 포함하는 약학적 조성물 |
BR112017019751A2 (pt) | 2015-03-18 | 2018-05-29 | Arvinas Inc | composto bifuncional, composição farmacêutica, e, métodos para tratar ou prevenir uma doença ou um distúrbio, e para degradar uma proteína alvo em uma célula |
US10683305B2 (en) | 2015-04-27 | 2020-06-16 | Concert Pharmaceuticals, Inc. | Deuterated OTX-015 |
US10772962B2 (en) | 2015-08-19 | 2020-09-15 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
AR106520A1 (es) | 2015-10-29 | 2018-01-24 | Incyte Corp | Forma sólida amorfa de un inhibidor de proteína bet |
EP3472157B1 (en) | 2016-06-20 | 2023-04-12 | Incyte Corporation | Crystalline solid forms of a bet inhibitor |
JP2021512153A (ja) | 2018-01-26 | 2021-05-13 | イエール ユニバーシティ | タンパク質分解のイミド系モジュレーターおよび使用方法 |
CN108070562A (zh) * | 2018-02-03 | 2018-05-25 | 金华市中心医院 | 一种“双打击”弥漫大b细胞淋巴瘤细胞系制备方法 |
IL310860A (en) | 2018-04-13 | 2024-04-01 | Arvinas Operations Inc | Servalon ligands and bifunctional compounds containing them |
US11883393B2 (en) | 2019-12-19 | 2024-01-30 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0661284A1 (en) | 1992-09-18 | 1995-07-05 | Yoshitomi Pharmaceutical Industries, Ltd. | Thienodiazepine compound and medicinal use thereof |
CN1109037C (zh) * | 1996-09-13 | 2003-05-21 | 三菱制药株式会社 | 噻吩并-三唑并二氮杂䓬化合物及其医药用途 |
CN101910182B (zh) * | 2007-12-28 | 2013-07-17 | 田边三菱制药株式会社 | 抗癌剂 |
JP5715241B2 (ja) * | 2010-05-14 | 2015-05-07 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | 新生物、炎症性疾患、およびその他の障害を治療するための組成物および方法 |
BR112012029005A2 (pt) * | 2010-05-14 | 2016-07-26 | Dana Farber Cancer Inst Inc | composições e métodos de tratamento de neoplasia, doença inflamatória e outros distúrbios |
WO2013033420A1 (en) * | 2011-08-30 | 2013-03-07 | Whitehead Institute For Biomedical Research | Methods of downregulating translocated oncogene expression using bromodomain inhibitors |
-
2013
- 2013-06-25 RU RU2015101106A patent/RU2659171C2/ru not_active IP Right Cessation
- 2013-06-25 IN IN11269DEN2014 patent/IN2014DN11269A/en unknown
- 2013-06-25 BR BR112014032105A patent/BR112014032105A2/pt not_active Application Discontinuation
- 2013-06-25 US US13/926,029 patent/US20140018353A1/en not_active Abandoned
- 2013-06-25 MX MX2014015986A patent/MX2014015986A/es unknown
- 2013-06-25 AU AU2013283378A patent/AU2013283378B2/en not_active Ceased
- 2013-06-25 KR KR20157000782A patent/KR20150045423A/ko active Search and Examination
- 2013-06-25 CA CA2877434A patent/CA2877434A1/en not_active Abandoned
- 2013-06-25 WO PCT/EP2013/063313 patent/WO2014001356A1/en active Application Filing
- 2013-06-25 CN CN201380045846.0A patent/CN105050605A/zh active Pending
- 2013-06-25 EP EP13730912.6A patent/EP2863923B1/en not_active Not-in-force
- 2013-06-25 JP JP2015517810A patent/JP6265979B2/ja not_active Expired - Fee Related
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016525563A (ja) * | 2013-08-01 | 2016-08-25 | オンコエシックス ゲーエムベーハー | チエノトリアゾロジアゼピン化合物を含む医薬製剤 |
Also Published As
Publication number | Publication date |
---|---|
CA2877434A1 (en) | 2014-01-03 |
EP2863923A1 (en) | 2015-04-29 |
BR112014032105A2 (pt) | 2017-08-01 |
AU2013283378B2 (en) | 2017-07-13 |
US20140018353A1 (en) | 2014-01-16 |
EP2863923B1 (en) | 2019-05-08 |
CN105050605A (zh) | 2015-11-11 |
JP2015531747A (ja) | 2015-11-05 |
KR20150045423A (ko) | 2015-04-28 |
WO2014001356A1 (en) | 2014-01-03 |
AU2013283378A1 (en) | 2015-01-29 |
IN2014DN11269A (ja) | 2015-10-09 |
RU2015101106A (ru) | 2016-08-10 |
MX2014015986A (es) | 2016-02-11 |
RU2659171C2 (ru) | 2018-06-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6265979B2 (ja) | チエノトリアゾロジアゼピン化合物を使用するリンパ腫の治療方法 | |
Tao et al. | The effects of NRF2 modulation on the initiation and progression of chemically and genetically induced lung cancer | |
Lu et al. | Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-κB signaling and depleting Bcr-Abl | |
Wang et al. | Inhibition of autophagy potentiates the anti‐metastasis effect of phenethyl isothiocyanate through JAK2/STAT3 pathway in lung cancer cells | |
Qin et al. | CDK4/6 inhibitor palbociclib overcomes acquired resistance to third‐generation EGFR inhibitor osimertinib in non‐small cell lung cancer (NSCLC) | |
Liu et al. | Synergistic killing of lung cancer cells by cisplatin and radiation via autophagy and apoptosis | |
Liu et al. | Apoptosis induced by benzyl isothiocyanate in gefitinib-resistant lung cancer cells is associated with Akt/MAPK pathways and generation of reactive oxygen species | |
Wong et al. | Preclinical evaluation of the PI3K-mTOR dual inhibitor PF-04691502 as a novel therapeutic drug in nasopharyngeal carcinoma | |
Leclerc et al. | The NEDD8-activating enzyme inhibitor pevonedistat activates the eIF2α and mTOR pathways inducing UPR-mediated cell death in acute lymphoblastic leukemia | |
Liu et al. | Inhibition of IGF1R enhances 2-deoxyglucose in the treatment of non-small cell lung cancer | |
Hussain et al. | A novel PI3K axis selective molecule exhibits potent tumor inhibition in colorectal carcinogenesis | |
Schmitt et al. | BRD4 inhibition sensitizes diffuse large B-cell lymphoma cells to ferroptosis | |
AU2019261718A1 (en) | Cancer treatment | |
EP3866799A2 (en) | Compositions and methods for treating vascular ehlers danlos syndrome and associated disorders | |
AU2018335617B2 (en) | Combination of a BTK inhibitor and an inhibitor of CDK9 to treat cancer | |
CN111163781A (zh) | 用于治疗癌症的mdm2抑制剂与erk抑制剂的组合 | |
Lee et al. | Simvastatin enhances the radiosensitivity of p53‑deficient cells via inhibition of mouse double minute 2 homolog | |
EP4333847A1 (en) | Compounds and compositions for the treatment of mpnst | |
AU2017354082A1 (en) | Combinations of FGFR4 inhibitors and bile acid sequestrants | |
Alejandra Pezuk et al. | Polo-like kinase 1 pharmacological inhibition as monotherapy or in combination: comparative effects of polo-like kinase 1 inhibition in medulloblastoma cells | |
KR102436875B1 (ko) | Pi3 키나아제 억제제 및 bcl-2 억제제를 포함하는 조성물 | |
EP4110331A1 (en) | Methods of treating dlbcl using btk inhibitors and combinations thereof | |
WO2015153866A1 (en) | Cancer therapy with ganetespib and an egfr inhibitor | |
Zuo et al. | BRD4 inhibition sensitizes aggressive non-Hodgkin lymphomas to PI3Kδ inhibitors by suppressing PI3K reactivation and c-MYC expression | |
Ganai et al. | Histone deacetylase inhibitors as sanguine epitherapeutics against the deadliest lung cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20160222 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20160222 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20160225 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160602 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160602 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170214 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170413 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170810 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20171205 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6265979 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |